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Purpose or Objective: Low-dose radiotherapy (LDRT) is a 
highly effective treatment in indolent non-Hodgkin 
lymphomas (NHLs). However, a reduced efficacy in aggressive 
lymphomas has never been demonstrated. We aimed to 
assess the effect of histologic type on disease response to 
LDRT. 
 
Material and Methods: Data from a clinical phase-II trial 
using LDRT for palliation in diffuse large B-cell lymphoma 
(DLBCL) patients were compared with clinical outcome of 
patients with follicular lymphoma (FL), marginal zone 
lymphoma (MZ), and mycosis fungoides (MF) which were 
treated with LDRT at our Institution in the same period. LDRT 
consisted of 4 Gy in 2 fractions on symptomatic areas only for 
both DLBCL and indolent NHLs. Bulky disease was defined as 
> 5 cm in maximum diameter. Chemoresistance was defined 
as the failure of chemo to achieve a complete or partial 
response, or as disease relapse after a complete response. 
Clinical response was assessed 21 days after LDRT, and was 
defined as reduction > 50% of maximum diameter of the 
radiated lesions. Response evaluation was performed with 
CT-scan or clinical exam for palpable lesion. Toxicity was 
scored using the CTCAE v3.0. 
 
Results: In all, 35 patients were evaluated. Sixteen were 
male; histologies were 17 DLBCL, 8 FL, 6 MZ, and 4 MF. 
Characteristics were generally balanced between the two 
groups. However, DLBCL patients were more likely to have 
bulky disease and chemoresistance. Median follow up was 7 
months (range, 1 – 49 months). No significative difference 
was noted concerning overall response rate between DLBCL 
and indolent NHLs (overall response rate was 70% (12/17) and 
83% (15/18) for patients with aggressive and indolent forms, 
respectively; p = 0.39), but indolent forms were associated 
with a higher rate of complete response (complete response 
rate was 61% (11/18) and 35% (6/17) for patients with 
indolent and aggressive NHL, respectively; p = 0.09). Only 1 
case of toxicity was noted (grade 2 nausea). The median 
duration of response was 7 months (range, 1 – 35 months). 
Among responders, only 2 patients progressed within the 
radiated field at the time of last follow-up visit. 
 
Conclusion: Efficacy of LDRT for DLBCL and indolent NHL 
patients resulted comparable in terms of overall response 
rate. Complete response rate was higher in the indolent NHL 
population than in the subset of DLBCL patients included in 
the phase II trial. 
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Purpose or Objective: Follicular lymphoma (FL) is an 
indolent disease with a progressive relapsing course. 
Autologous hematopoietic cell transplantation (AHCT) has 
been proven to be effective in treating recurrences. At The 
Ottawa Hospital (TOH), AHCT utilizing total body irradiation 
(TBI) has been used to treat FL patients, who have progressed 
after at least one course of chemotherapy, for over 20 years. 
There are concerns in the literature regarding the use of TBI 
due to the potential for radiation-induced second 
malignancies. However, we hypothesize that TBI based 
conditioning regimens should not lead to excessive second 
cancers. We undertook a review of our large single-institution 
AHCT experience in order to assess patient outcomes and 
rates of second malignancy. 
 
Material and Methods: We retrospectively reviewed 
consecutive patients undergoing AHCT for relapsed FL from 
July 1991 to February 2013. All patients received treatment 
at TOH, a regional tertiary center. The most common pre-
AHCT conditioning regimen was Etoposide 60 mg/kg / 
Melphalan 140 mg/m2 / TBI. Patients received TBI on a linear 
accelerator using high energy photons (10MV or 18MV) and 
utilizing a translating bed technique. 92% received 5 Gy / 
1fraction / 1day, the rest received 12 Gy / 6 fractions / 3 
days. Lung attenuators were used for all patients to maintain 
a homogeneous dose. Patient information was stored in our 
bone marrow transplant registry database. This includes 
baseline characteristics, demographics, outcomes, types and 
dates of second cancers. Descriptive statistics were 
calculated for all relevant demographic variables. Overall 
survival of the cohort was estimated using the Kaplan-Meier 
method. Cumulative incidence of second malignancy was 
calculated; death was a competing risk. 
 
Results: Overall, we evaluated 174 patients with a median 
age of 50 years at transplant. There were 106 men and 68 
women included, and median follow-up was 6.0 years after 
AHCT. Overall survival at 1, 5, 10 and 15 years was 93%, 73%, 
57% and 47% respectively. The median follow-up among 
survivors was 8.3 years. Eighteen of 174 patients (10.3 %) 
developed a second malignancy. Of these, 11 (6.3%) had solid 
tumors, 2 (1.1%) had AML and 5 (2.9%) developed 
myelodysplastic syndrome. Median time to second malignancy 
was 7.2 years, with cumulative incidences of developing 
second cancer at approximately 4.5% and 8.2% at 5 and 10 
years. Solid tumors included breast (2), prostate (3), 
endometrial (1), skin (4) and lung cancers (1). Furthermore, 
82% of patients who developed solid tumors were alive at last 
follow-up. 
 
Conclusion: Our results with AHCT utilizing TBI in the 
management of relapsed FL patients have been very good. 
Indeed, most patients survive more than 10 years after 
treatment. The risk of second cancers is acceptable and 
compares favorably with the published literature. Moreover, 
we suspect screening, particularly for solid tumors post-
treatment, may help detect early treatable second 
malignancies. 
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Purpose or Objective: Mucosa-associated lymphoid tissue 
(MALT) lymphoma can present in several sites in the head and 
neck and is often treated with radiotherapy. MALT lymphoma 
of the salivary and lacrimal glands is >300 fold more common 
in patients with Sjogren’s syndrome (SS) than in the rest of 
the population and tends to be a multifocal process. The 
optimal dose of radiotherapy is not established. The aim of 
this study is to analyse the outcome of radiotherapy for head 
and neck MALT lymphoma in patients with and without SS. 
 
Material and Methods: A retrospective review of 
departmental records identified 26 patients with head & neck 
MALT lymphoma treated with radiotherapy between 2003-
2013. Inclusion criteria were histologically proven MALT 
lymphoma and complete radiotherapy record. The primary 
end-points were objective response rate and response 
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duration. Median age was 61 years (range 30-83). Fourteen 
patients had confirmed SS. Eighteen patients were female (12 
with SS) and 8 were male (2 with SS). Stage of disease 
includes: stage 1 (17 patients) stage 2 (7), stage 3 (1) and 
stage 4 (1). Patients with SS were treated with 4Gy and 
patients without SS were treated with 25.2Gy, unless they 
had advanced stage. Sites treated include: parotid (13 
patients), orbit or conjunctiva (6), thyroid (1), tongue (1), 
palate (4) & spine (1) Indications for treatment included 
pain, recurrent inflammation or unsightly mass. 17 patients 
received 4 Gy in 2 fractions (13 with SS) and 9 patients 
received 25.2 Gy in 14 fractions (1 with SS). 
 
Results: The objective response rate (ORR= CR + PR, assessed 
6 weeks after RT) was 100%. Twenty-two patients (84.6%) 
remain progression-free at the time of writing with median 
FU of 89 months (range 22 - 144). Two males (1 with SS) and 
one female had disease progression in the treated area at 3, 
36 and 19 months respectively. All 3 relapses occurred in 4Gy 
dose group. Two patients were subsequently retreated with 
further 4Gy/2# and 20Gy/5# and achieved further 
progression-free survival of 36 and 60 months respectively. 
One female patient (4Gy/2#) underwent transformation to 
diffuse large B-cell lymphoma at 36 months. The distribution 
of relapses is summarised in table 1. Radiotherapy was well 
tolerated in all patients, with the most common long-term 
side effect being dry mouth in 3 patients (11.5%), cataract in 
1 patient and watery eye in 1 patient. All three patients who 
reported dry mouth were known to have SS. 
 
Conclusion: Radiotherapy is a very effective treatment for 
head and neck MALT lymphoma resulting in high response 
rate, durable local control and minimal toxicity. There were 
no relapses after 25.2Gy and only few relapses (3/17) after 
4Gy, 2 of which had durable remission following re-
treatment. 
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Purpose or Objective: The purpose of this study was to 
estimate risk and incidence of second malignant neoplasms 
(SMN) among long-term survivors of early stage extranodal 
nasal-type natural killer/T-cell lymphoma (NKTCL). 
 
Material and Methods: Between January 1983 and December 
2007, 174 patients with stage IE and IIE NKTCL survived 3 or 
more years after treatment. Of them, 50 patients were 
treated with radiotherapy alone, 120 patients with combined 
modality therapy, and 4 patients with chemotherapy alone. 
The China 2010 population census data and Segi’s world 
population data were used for calculating the age-
standardized cancer incidence rates. 
 
Results: Median follow-up time was 8.3 years (range, 3.1 - 
35.6 years) for all patients. Nine (5.2%) SMNs were recorded. 
The median time to SMN was 12.6 years (range, 0.9 - 18.5 
years) from diagnosis of NKTCL. Seven patients had solid 
tumors, and 2 had other type of malignant lymphomas. The 
cumulative incidence rates at 5-year, 10-year and 15-year 
were 1.2%, 2.4%, and 13.7% (Figure), respectively. The crude 
incidence was 531.6/105 person-years, the age-standardized 
rates by Chinese standard population (ASR China) and by 
world standard population (ASR world) were 294.5/105 and 
243.7/105, and the cumulative incidence rate (0-74 age years 
old) was 22.4%. All of them were higher than the cancer 
incidence rates for general population in China in 2010. 
 
 
Conclusion: A frequency of SMN in patients with NKTCL is 
higher than expected in the general population. The patients 
have more risk for SMN during 10 to 15 years after diagnosis 
of NKTCL. Patients with long-term survivor are at higher risk 
of SMN and should be carefully follow-up. 
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Purpose or Objective: Low dose radiotherapy (LDRT) 
provides effective palliation and local disease control in 
patients with low grade non Hodgkin lymphoma (LGNHL). Its 
role in high grade NHL (HGNHL) remains unclear.  
The purpose of this study was to evaluate the efficacy of 
LDRT in relapsed/refractory (RR) HGNHL.  
 
Material and Methods: We performed a retrospective review 
of all patients undergoing LDRT for RR HGNHL at our 
institution. LDRT was defined as a total dose of 8Gy or less in 
1 or more fractions.  
Sex, age, histological type, time from diagnosis to LDRT and 
number of prior systemic therapies were recorded, along 
with radiotherapy dose and site treated.  
Outcomes included overall response rate (ORR), in field 
recurrence, time to progression (TTP) and overall survival 
from completion of RT. Toxicity was also recorded. Analysis 
was performed by site and by patient as a number of patients 
had more than 1 site treated at different times.  
 
Results: Between August 2004 and September 2015 15 
patients received LDRT for HGNHL. 5 patients had >1 site 
treated, with LDRT being given to 37 sites in total. Most 
patients (12/15) had a diagnosis of diffuse large B cell 
lymphoma, which accounted for 32/37 (86.5%) of all sites. 
Patient and treatment characteristics are shown in table 1.  
